Announced
Completed
Koch Disruptive Technologies led a $215m Series B round in Immunai.
Synopsis
Koch Disruptive Technologies led a $215m Series B round in Immunai, a New York-based biotech company, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont and ICON. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.